Scarica l'app Stockscreener
3.07
2.33%
0.07
Dopo l'orario di chiusura:
3.10
0.03
+0.98%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.00
Aprire:
$3
Volume 24 ore:
1.18M
Relative Volume:
1.18
Capitalizzazione di mercato:
$232.86M
Reddito:
-
Utile/perdita netta:
$-45.62M
Rapporto P/E:
-5.1649
EPS:
-0.5944
Flusso di cassa netto:
$-62.34M
1 W Prestazione:
+3.72%
1M Prestazione:
+15.41%
6M Prestazione:
+11.23%
1 anno Prestazione:
-7.25%
Intervallo 1D:
$2.90
$3.145
Intervallo di 1 settimana:
$2.68
$3.1674
Portata 52W:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Nome
Eledon Pharmaceuticals Inc
Settore
Industria
Telefono
949-238-8090
Indirizzo
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.07 | 232.86M | 0 | -45.62M | -62.34M | -0.5944 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-18 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Guggenheim | Buy |
| 2022-05-13 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-03-23 | Iniziato | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Borsa (ELDN) Ultime notizie
Eledon Pharmaceuticals Inc (2TK.SG) - Yahoo! Finance Canada
ELDN Forecast, Price Target & Analyst Ratings | ELEDON PHARMACEUTICALS INC (NASDAQ:ELDN) - ChartMill
Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Rises By 30.3% - MarketBeat
Eledon Pharmaceuticals (ELDN) Price Target Decreased by 14.93% to 8.33 - MSN
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Geopolitics Watch: What hedge funds are buying Eledon Pharmaceuticals Inc2026 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn
Vanguard disaggregates holdings after realignment; Eledon (ELDN) showing 0 shares - Stock Titan
What is Noble Financial's Forecast for ELDN Q1 Earnings? - MarketBeat
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans? - Sahm
Midday Stock Roundup: RxSight Climbs 7% - Orange County Business Journal
Eledon Unveils New Type 1 Diabetes Data - Orange County Business Journal
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings | 2TK | US28617K1016 - marketscreener.com
If You Invested $1,000 in Eledon Pharmaceuticals Inc (ELDN) - Stock Titan
Eledon Pharmaceuticals Reports Positive 2025 Results for Tegoprubart in Transplant Trials and Receives FDA Orphan Drug Designation - minichart.com.sg
Eledon Pharmaceuticals, Inc. 2026 Annual Report: Business Overview, Risk Factors, and Strategic Focus on Immunology and Tegoprubart Development 29 - Minichart
Eledon Pharmaceuticals (NASDAQ:ELDN) Announces Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
ELEDON PHARMACEUTICALS ($ELDN) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
Eledon Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results - The Manila Times
Eledon Pharmaceuticals 2025 net loss widens on higher R&D costs - TradingView
Eledon (NASDAQ: ELDN) 2025 results show higher R&D spend and cash - Stock Titan
Tegoprubart data and new orphan status headline Eledon (NASDAQ: ELDN) 2025 update - Stock Titan
Eledon Pharmaceuticals options imply 11.7% move in share price post-earnings - TipRanks
ELDN PE Ratio & Valuation, Is ELDN Overvalued - Intellectia AI
Eledon reports insulin independence in islet transplant trial By Investing.com - Investing.com Australia
Leerink Maintains Outperform on ELDN (Eledon Pharmaceuticals) March 16, 2026 - Meyka
Eledon Pharmaceuticals (ELDN) Presents Promising Diabetes Trial Results - GuruFocus
Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tego - GuruFocus
Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative - Seeking Alpha
Eledon’s Transplant Drug Is Heading Toward A Phase 3 Moment - Finimize
Leerink Partners reiterates Outperform on Eledon stock at $5 By Investing.com - Investing.com Canada
Eledon announces updated data from investigator-initiated islet transplant trial of tegoprubart in patients with type 1 diabetes at UChicago Medicine - marketscreener.com
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine - Bitget
Eledon reports insulin independence in islet transplant trial - Investing.com
Eledon Pharmaceuticals Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Experimental transplant drug lets 10 diabetes patients stop insulin - Stock Titan
Eledon Pharmaceuticals Touts Tegoprubart Safety in BESTOW Kidney Transplant Data at Leerink Conference - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Eledon Pharmaceuticals (ELDN) to Release Quarterly Earnings on Thursday - MarketBeat
Eledon Pharmaceuticals at Leerink Conference: Strategic Insights on Transplantation By Investing.com - Investing.com Canada
ELDN: Tegoprubart advances with strong safety data, phase 3 plans, and cash runway into Q2 2025 - TradingView
NewcelX partners with Eledon on type 1 diabetes therapy By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals Announces Orphan Drug Designation - GlobeNewswire
Eledon's Tegoprubart Gets FDA's Orphan Drug Designation In Liver Transplantation; Stock Up - RTTNews
Eledon Pharma wins FDA orphan status for lead asset (ELDN) - Seeking Alpha
Eledon Pharmaceuticals (ELDN) Gains FDA Orphan Drug Status for T - GuruFocus
FDA gives rare-disease status to drug aiming to protect liver transplants - Stock Titan
NewcelX and Eledon partner for NCEL-101 programme - Yahoo Finance
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation - Bitget
Newcelx partners with Eledon to advance NCEL-101 - BioWorld MedTech
Eledon Pharmaceuticals Inc Azioni (ELDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):